人胰升糖素样肽-1类似物利拉鲁肽临床作用探讨
摘要
2型糖尿病已成为全球范围内发病率增长最快的疾病之一,我国目前有9200万糖尿病患者和1.55亿糖尿病前期患者,胰岛功能的进行性衰退,包括β细胞胰岛素分泌缺陷和仅细胞升糖素不适当的分泌是2型糖尿病发生发展的重要原因。UKPDS显示,在2型糖尿病诊断时,患者胰岛β细胞功能已降至正常的50%,且随病程的延长,
出处
《实用糖尿病杂志》
2014年第4期58-59,共2页
Journal of Practical Diabetology
参考文献23
-
1Del Prates, Marahetti P. Beta-and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res 2004;36:775 -781.
-
2Matthews DR, Cull CA, Stratton IM, et al. UKPDS26 : sulph- onylu failure in non-insulin-dependent diabetic patients over six years. Uk Prospective Diabetes Study ( UKPDS ) Group. diabetes Med 1998 ; 15:297 - 303.
-
3朱大龙,李平.DPP-4抑制剂的作用机制及在2型糖尿病治疗中的应用[J].中华内分泌代谢杂志,2011,27(11). 被引量:13
-
4Ahren B, Picini G. Islet adaptation to insulin resistance : medi- anisms for intervention. Diabetes Obes Metab 2005 ;7:2 - 8.
-
5冯凭.2型糖尿病胰岛功能障碍与基于肠促胰素的治疗[J].中华内分泌代谢杂志,2011,27(11). 被引量:4
-
6潘长玉.从近期研究看GLP-1对心血管的作用[J].中华内分泌代谢杂志,2010,26(5):437-440. 被引量:10
-
7纪立农.肠促胰素在2型糖尿病治疗中的作用[J].中华内分泌代谢杂志,2010,26(8):737-740. 被引量:11
-
8Druckr DJ, Nauck MA. The incretin system: glucagons-like peptide 1 reeepter agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 ;368 : 1696 - 1705.
-
9Salehi M,Aulinger BA,D ' Alessio DH. Targeting beta-cell massm in type 2 diabetes:promise and limitations of new drugs based on incretins. Endocr Rev 2008 ;29:367 - 379.
-
10Davies MJ, Kela R, khunti K, et al. liraglutide-overview of the predinical and dinical data and its role in the treatment of type 2 diabe- tes. Diabetes Obes Metab 2011 ; 13:207 - 220.
二级参考文献192
-
1胡仁明,李洪超.胰高血糖素样多肽-1类药治疗2型糖尿病的复合终点评价[J].中华糖尿病杂志,2010,2(4). 被引量:16
-
2UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucoee control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).Lancet,1998,352:837-853.
-
3Haffner SM,Lehto S,R(o)nnemaa T,et al.Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.N Engl J Med,1998,339:229-234.
-
4Drucker DJ,Nauck MA.The incretin system-glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.Uncet,2006,368,1696-1705.
-
5Salehi M,Aulinger BA,D'Alessio DA.Targeting beta-cell mass in type 2 diabetes; promise and limitations of new drugs based on incretins.Endocr Rev,2008,29:367-379.
-
6Grieve DJ,Cassidy RS,Green BD.Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1:potential therapeutic benefits beyond glycaemic control? Br J Pharmacol,2009,157,1340-1351.
-
7NystromT,Gutniak MK,Zhang Q,et al.Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.Am J Phsiol Endocrinol Metab,2004,287:E1209-E1215.
-
8Nikolaidis LA,Doverspike A,Hentosz T,et al.Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines.J Pharm Exp Ther,2005,312:303-308.
-
9Nikolaidis LA,Elahi D,Hentosz T,et al.Recombinant.Glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy.Circulation,2004,110:955-961.
-
10Sokos G,Nikolaidis LA,Mankad S,et al.Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.J Cardiac Fail,2006,12:694-699.
共引文献93
-
1史视明,刘亚辉,马亮,吴丽丽.初发2型糖尿病患者餐后胰高糖素样肽-1分泌模式[J].南昌大学学报(医学版),2011,51(11):50-52. 被引量:1
-
2张存志,秦恒斌,邸力强,曹瑞芳.人胰升糖素样肽-1类似物利拉鲁有为减轻2型糖尿病患者体重及减少低血糖风险的作用[J].实用糖尿病杂志,2012,8(2):43-44. 被引量:8
-
3李华.治疗2型糖尿病的新力量——GLP-1类似物利拉鲁肽[J].求医问药(下半月刊),2012,10(6):197-198. 被引量:9
-
4高君,孟繁杰.利拉鲁肽对大剂量胰岛素控制不佳患者高胰岛素血症影响[J].中国实验诊断学,2013,17(5):950-951. 被引量:2
-
5胡瑛,苏欣,刘灵佳,向宇飞,余琪琪,易受南,周智广.胰升糖素样肽1类似物利拉鲁肽对正常人和1型糖尿病患者CD4+CD25-T细胞增殖的影响[J].中华内分泌代谢杂志,2013,29(6):474-478. 被引量:3
-
6宋颖,魏巍.健康教育配合利拉鲁肽单药治疗新诊断超重2型糖尿病的临床分析[J].实用药物与临床,2013,16(6):499-500. 被引量:3
-
7郭颖,吴波.利拉鲁肽联台胰岛素治疗肥胖或超重的2型糖尿病患者观察[J].实用糖尿病杂志,2013,9(3):39-41. 被引量:7
-
8钱毅,郭晓辉.利拉鲁肽治疗左心室舒张功能不全的Ⅱ型老年糖尿病患者临床观察[J].西部医学,2013,25(10):1524-1525. 被引量:3
-
9苏向辉,孙侃,宋学锋,常向云,叶芳,王艳丽.沙格列汀治疗老年糖尿病对肝、肾、心功能的影响[J].中国老年学杂志,2013,33(20):4978-4979. 被引量:14
-
10宋仪利,刘昌盛.利拉鲁肽治疗2型糖尿病临床观察[J].现代中西医结合杂志,2013,22(33):3708-3710. 被引量:1
-
1周新丽(译校).晚期糖基化终末产物是胰岛β细胞功能的调节剂[J].中华糖尿病杂志,2012,4(1):61-61.
-
2胰升糖素样肽—1对空腹血糖较低的糖尿病患者更有效(J Clin Endocrin Metab,2001,86:3853—3860)[J].国外医学(内分泌学分册),2002,22(1):60-60.
-
3张家庆.2型糖尿病患者会同时存在胰岛素分泌缺陷和抵抗吗?[J].糖尿病之友,2005(9):56-56.
-
4于棉荣.您该如何选择磺脲类降糖药?[J].糖尿病新世界,2009(10):26-26.
-
5单利珍,任跃忠.胰升糖素样肽-1及类似物的临床研究进展[J].国外医学(老年医学分册),2005,26(4):167-171.
-
6仝小林,王佳.经典降糖药,安全效更高[J].糖尿病天地(临床),2008(9):440-440.
-
7孙美珍.2型糖尿病血脂异常[J].糖尿病天地,2009(3):35-35.
-
8刘安诺,彭巧君.2型糖尿病患者输注不同比例配制的葡萄糖胰岛素溶液对血糖的影响[J].中国实用护理杂志(中旬版),2009,25(4):28-29.
-
9张存志,秦恒斌,邸力强,曹瑞芳.人胰升糖素样肽-1类似物利拉鲁有为减轻2型糖尿病患者体重及减少低血糖风险的作用[J].实用糖尿病杂志,2012,8(2):43-44. 被引量:8
-
10王鹏虎,宋留生,王晓青.诺和锐30R治疗初发2型糖尿病60例的临床观察[J].实用糖尿病杂志,2008,4(1):64-64. 被引量:3